# The pharmaceutical and biotech industries are pushing back against two Trump administration proposals.

*biotech · news · 2026-02-24 · STAT*

## Key points

- Pharmaceutical and biotech industries oppose two Trump proposals to lower Medicare drug prices.
- The proposals would align Medicare drug prices with those paid in other wealthy countries.
- The planned Medicare pilot programs would be mandatory and run for five years.
- Drugmakers may pursue legal challenges once the proposals are finalized.

WASHINGTON — The pharmaceutical and biotech industries are pushing back against two Trump administration proposals that would test plans to lower drug prices in Medicare by aligning them with the prices paid in other rich countries. Their comments preview arguments that they might use in court against the Medicare pilot programs, which would be mandatory and run for five years. It’s too soon for drugmakers to mount legal challenges, because the pilots are still in the proposal phase, and drugmakers would have to wait until they’re finalized to file lawsuits. Advertisement

**Countries:** United States

[Read the full story on STAT](https://www.statnews.com/2026/02/24/pharma-opposition-medicare-drug-price-pilot-programs-strategy-emerges/)

---

Canonical: https://newsio.io/n/c95ca783-8287-49ec-bcc5-054d89a73287/the-pharmaceutical-and-biotech-industries-are-pushing-back-against-two-trump-adm
Summarized by Newsio from STAT. https://newsio.io/how-it-works